←
Jayant Siva8 posts
Jayant Siva avatar✓

Jayant Siva ✓

@jaymsiva

Medical Student @cwru | Prev Research Fellow @cleclinicuro

◷ Joined June 2025
Laura Bukavina avatar
⟳ Jayant Siva retweeted
Laura Bukavina@LauraBukavinaMD·Nov 5

Congrats @jaymsiva on this clinically important publication .. 🤔what to do with urothelial typical of unknown significance (AUS) and odds of BC development ❓always struggle in clinic 💥Largest contemporary series of de novo urothelial atypia (n=103)5-yr bladder cancer risk 6.5% with AUS median time to progression 1.7 years 🫵🏻Perhaps scoping again in 1-2 years may not be a bad idea

Post attachmentPost attachment
Bryan Naelitz, MD, MS avatar
⟳ Jayant Siva retweeted
Bryan Naelitz, MD, MS@BlitzUro·Aug 21

Does semen volume change after a vasectomy? Our retrospective case-control study of 957 patients found that vasectomy was not associated with a change in semen volume, evidence that can strengthen patient counseling before the procedure. Check it out: doi.org/10.1111/andr.70359

Post attachment
Ashish M. Kamat, MD, MBBS avatar
⟳ Jayant Siva retweeted
Ashish M. Kamat, MD, MBBS@UroDocAsh·Jun 12

Congratulations to @LauraBukavinaMD @jaymsiva @drjkaouk and @ClevelandClinic team on largest external validation of the IBCG IR NMIBC substratification model 📊 2822 patients | 20 years | 3-year recurrence by subgroup: 🟢 IR-low: 12% 🟡 IR-intermediate: 38% 🔴 IR-high: 77% Progression followed the same stepwise pattern. Fine-Gray competing-risk models confirmed significance (p<0.001) - separation held on 12-month landmark analysis, ruling out early-event bias. Yet more evidence that trials enrolling IR NMIBC should stratify by IBCG subgroup at enrollment to be clinically meaningful. Conflating patients with 12% and 77% recurrence risk in the same trial arm is a fundamental problem. Full text: authors.elsevier.com/sd/arti… @IBCG_BladderCA

Post attachmentPost attachment